NADH

NADH (Reduced Nicotinamide Adenine Dinucleotide)

1. Identity

Chemical and Common Names

NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H)." NADH (nicotinamide adenine dinucleotide in its reduced form) is a physiological substance found in all living cells, including human cells, acting as an activating factor of various enzymes that catalyze oxidation and reduction reactions. It is also known in the literature as reduced NAD, NADH+H⁺, and sometimes as Coenzyme 1 or Co-E1. NADH, biologically known as Coenzyme 1 (as it is the most important co-enzyme, also known as Co-E1), is necessary for thousands of biochemical reactions within the body and is found naturally in every living cell.

Chemical Structure

Nicotinamide adenine dinucleotide is a coenzyme found in all living cells. The compound is a dinucleotide, since it consists of two nucleotides joined through their phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide. The coenzyme is found in two forms in cells: NAD+, that is an oxidizing agent—it accepts electrons from other molecules and becomes reduced forming NADH, which can then be used as a reducing agent to donate electrons. These two forms differ by a single hydride ion (H⁻). A hydride is a hydrogen atom that carries an extra electron, which gives it a negative charge. NAD+ becomes NADH by accepting this hydride during metabolic reactions. The process turns NAD+'s positive charge into NADH's neutral charge.

Natural Sources

NADH is found in all living cells, animal or vegetable. It is consequently also found in daily food intake. Meat, poultry, and fish contain the highest share of NADH. The highest concentration of NADH in animals is found in muscle tissues, which means that meat might be a good source, were it not that most of the NADH in meat is destroyed during processing, cooking, and digestion. In reality, people do not get much NADH from their food. NADH is found in the muscle tissue of fish, poultry, and cattle, as well as in food products made with yeast. However, it is not known whether the NADH from these sources can be efficiently absorbed or utilized by the body.

Healthy bodies make all the NADH they need, using vitamin B3 (also known as niacin or nicotinamide) as a starting point. In organisms, NAD+ can be synthesized from simple building-blocks (de novo) from the amino acids tryptophan or aspartic acid. In an alternative fashion, more complex components of the coenzymes are taken up from food as the vitamin called niacin.

Common Forms and Preparations

As a dietary supplement, NADH is currently commercialized to help boost energy and add vitality to the human body. Commercially available NADH supplements present significant formulation challenges because NADH is chemically unstable outside of a living cell. A patented stabilized form, known as ENADA (Enzymatic NAD with Adenine), was developed and has been used in the majority of published clinical trials. Supplements are available in several delivery forms, including enteric-coated tablets (designed to survive stomach acid), sublingual lozenges, and oral capsules. Typical supplemental dosages range from 5 to 50 mg daily, often administered sublingually.

2. Traditional and Historical Use

NADH as an isolated, characterized molecule is a product of twentieth-century biochemistry rather than traditional medicine. It does not appear in pre-modern herbal pharmacopeias, folk medicine traditions, or ethnobotanical records in any identifiable form. NADH deficiency is known to occur only in the presence of vitamin B3 deficiency, which is rare in Western society except in some alcoholics. The concept of supplementing with NADH directly emerged from laboratory biochemistry rather than from any herbal, botanical, or indigenous healing tradition.

The therapeutic investigation of NADH as a supplement originated largely in Austria in the late 1980s and 1990s, primarily through the work of Georg Birkmayer, M.D., Ph.D., whose group developed the first stabilized oral NADH preparation and conducted early clinical investigations in Parkinson's disease. Healthcare providers sometimes give NADH by intramuscular (IM) or intravenous (IV) injection for Parkinson's disease and depression. These early intravenous and intramuscular applications in European clinical settings preceded the oral dietary supplement market. The transition from a parenteral hospital-administered compound to an over-the-counter oral supplement occurred through the 1990s as stabilization technologies improved.

3. Key Constituents, Active Compounds, and Mechanisms of Action

The NAD+/NADH Redox Couple

NADH represents the reduced form of NAD+, and together they constitute the two forms of nicotinamide adenine dinucleotide whose balance is named as the NAD+/NADH ratio. The NAD+/NADH ratio is mainly involved in redox reactions since both molecules are responsible for carrying electrons to maintain redox homeostasis. The intracellular NAD+/NADH ratio controls the rate of ATP synthesis by regulating flux through NAD(H)-linked dehydrogenases and by activating NAD+-dependent enzymes that post-translationally modify proteins.

Energy Production (ATP Synthesis)

The prime function of NADH is to stimulate cell breathing activity, while using up oxygen to form water and three molecules of ATP, an energy-rich compound available in all living cells. NADH triggers the production of energy by generating ATP, and acts as a primary activating enzyme capable of controlling the oxidation and reduction mechanisms of the cells' metabolic processes.

The cellular pathways of glycolysis and the tricarboxylic acid (TCA) cycle are metabolic hubs where NADH production happens through oxidation-reduction reactions. NADH plays a key role in cellular respiration by moving electrons from food molecules to the electron transport chain. This process leads to ATP synthesis. NADH dehydrogenase helps transfer electrons at Complex I of the respiratory chain. Mitochondria's energy-providing function is directly dependent on enzymes and coenzymes contained within the organelle. Perhaps, the most important coenzymes for energy-yielding reactions are the pyridine nucleotides NAD(H) and NADP(H). Both aerobic and anaerobic metabolism rely on the electron-carrying properties of pyridine nucleotides to regulate energy production.

CoQ10 and the reduced form of nicotinamide adenine dinucleotide (NADH) are key components of the electron transport chain responsible for mitochondrial ATP production, which decreases free radical generation, and, in their reduced forms, they act as powerful antioxidants.

Neurotransmitter Synthesis

NADH also stimulates the cellular production of neurotransmitters such as dopamine, noradrenaline and serotonin, hence improving mental concentration and muscle movements. The mechanism by which NADH influences dopamine synthesis has been studied at the cellular level: incubation of rodent cells with NADH leads to increased dopamine biosynthesis via elevated recycling of quinonoid dihydrobiopterin to tetrahydrobiopterin. Tetrahydrobiopterin is a cofactor necessary for the synthesis of tyrosine hydroxylase, a rate-limiting enzyme in dopamine production. This dopaminergic mechanism has been the principal rationale for NADH studies in Parkinson's disease.

Non-Redox Cellular Functions

NAD+ is also an essential cofactor for non-redox NAD+-dependent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases. NAD+ can directly and indirectly influence many key cellular functions, including metabolic pathways, DNA repair, chromatin remodelling, cellular senescence and immune cell function. These cellular processes and functions are critical for maintaining tissue and metabolic homeostasis and for healthy ageing.

Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide cofactor that is present in cells and in several important biological processes, including oxidative phosphorylation and production of adenosine triphosphate, DNA repair, calcium-dependent secondary messenger, and gene expression.

Antioxidant Activity

A lowered NAD+/NADH ratio has been shown to be associated with aging muscle and increased susceptibility to oxidative stress in catabolic organs. Oxidative stress-induced NAD+ depletion could play a significant role in the aging process, by compromising energy production, DNA repair, and genomic surveillance.

Age-Related Decline in NAD Levels

Ageing is accompanied by a gradual decline in tissue and cellular NAD+ levels in multiple model organisms, including rodents and humans. This decline in NAD+ levels is linked causally to numerous ageing-associated diseases, including cognitive decline, cancer, metabolic disease, sarcopenia and frailty. Total levels of NAD decline with age in a tissue-specific manner, thereby playing a significant role in the aging process. This age-associated decline has provided the primary biological rationale for NADH supplementation research.

4. Scientific Evidence by Area of Use

Overview of the Evidence Base

There is growing interest in NADH as a potential therapeutic supplement, especially for age-related conditions, though scientific research on its efficacy is limited. Based on these basic biochemical facts, NADH has been evaluated as a treatment for jet lag, Alzheimer's disease, Parkinson's disease, chronic fatigue syndrome, and depression, and as a sports supplement. However, only the first of these uses has any meaningful scientific evidence behind it, and even that is highly preliminary.

A 2024 systematic review of randomized clinical trials evaluated the body of evidence comprehensively: this systematic review performed a search in six electronic databases: PubMed, MEDLINE (Ovid), Embase, Cochrane CENTRAL (clinical trials), Web of Science, and Scopus. Two reviewers assessed and extracted the studies independently. The risk of bias in studies was performed using version 2 of the Cochrane risk of bias tool for randomized trials. This review includes 10 studies, with a total of 489 participants. The studies included different clinical conditions, such as chronic fatigue syndrome (CFS), older adults, Parkinson's disease, overweight, postmenopausal prediabetes, and Alzheimer's disease.

Jet Lag and Cognitive Performance Under Sleep Deprivation

This is the area with the most consistently positive, if still preliminary, clinical evidence. Because NADH increases cellular production of ATP and facilitates dopamine synthesis, it may counteract the effects of jet lag on cognitive functioning and sleepiness. Thirty-five healthy, employed subjects participated in this double-blind, placebo-controlled study. All participants completed computer-administered tests (including CogScreen) to assess changes in cognitive functioning, mood, and sleepiness in the morning and afternoon. Jet lag resulted in increased sleepiness for over half the participants and deterioration of cognitive functioning for approximately one third. The morning following the flight, subjects experienced lapses of attention in addition to disruptions in working memory, divided attention, and visual perceptual speed. Individuals who received NADH performed significantly better on 5 of 8 cognitive and psychomotor test measures (P ≤ 0.05) and showed a trend for better performance on the other three measures (P ≤ 0.10).

Some studies indicate that NADH may enhance cognitive function under sleep-deprived conditions, but more robust clinical trials are needed to establish its safety and effectiveness comprehensively. The evidence for this indication, while the strongest available for NADH, is nonetheless based on a small number of trials with limited sample sizes. The NASA Technical Reports Server lists the jet lag study, indicating the involvement of a NASA flight surgeon in the research.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)

ME/CFS has been a significant area of NADH research, particularly in combination with Coenzyme Q10 (CoQ10). CoQ10 and NADH levels and redox status have been shown to be disturbed in ME/CFS. Strong evidence has emerged that mitochondrial dysfunction, disturbed immunometabolism, and increased oxidative stress play a pivotal role in the pathogenesis of numerous illnesses, providing a robust scientific rationale for testing potential nutraceuticals that target these processes.

One of the key early trials by Castro-Marrero and colleagues: an 8-week, randomized, double-blind placebo-controlled trial was conducted to evaluate the benefits of oral CoQ10 (200 mg/day) plus NADH (20 mg/day) supplementation on fatigue and biochemical parameters in 73 Spanish CFS patients. This study was registered in ClinicalTrials.gov (NCT02063126). Furthermore, the CoQ10 plus NADH combination induced a significant reduction of fatigue, decrease in oxidative damage, improvement of mitochondrial function, and enhancement of energy showing a potential role in the physiopathology of the condition.

A subsequent proof-of-concept trial confirmed some signals: a proof-of-concept, 8-week, randomized, controlled, double-blind trial was conducted in 80 CFS patients assigned to receive either CoQ10 plus NADH supplementation or matching placebo twice daily. Maximum HR was evaluated at baseline and at end of the run-in period using an exercise test. Fatigue, pain and sleep were evaluated at baseline, and then reassessed at 4- and 8-weeks through self-reported questionnaires. The results suggest that CoQ10 plus NADH supplementation for 8 weeks is safe and potentially effective in reducing max HR during a cycle ergometer test and also on fatigue in CFS. Further additional larger controlled trials are needed to confirm these findings.

A larger, follow-on trial enrolled 207 ME/CFS patients: a 12-week prospective, randomized, double-blind, placebo-controlled trial was conducted in 207 patients with ME/CFS, who were randomly allocated to one of two groups to receive either 200 mg of CoQ10 and 20 mg of NADH (n = 104) or matching placebo (n = 103) once daily. The remaining 144 cases of ME/CFS (70%, 72 patients in each treatment group) completed all the study protocol procedures and were included in the overall analysis. Patients randomized to the CoQ10 plus NADH experimental group received four enteric-coated tablets daily consisting of active ingredients (50 mg of CoQ10 and 5 mg of NADH) and excipients.

Overall, findings support that the oral administration of NADH can be associated with an increase in general quality of life and improvement on health parameters (e.g., a decrease in anxiety, maximum heart rate, inflammatory cytokines in serum, and cerebrospinal fluid). However, the evidence is characterized as preliminary and confounded by the co-administration of CoQ10 in most CFS trials, making it difficult to isolate the independent contribution of NADH.

Alzheimer's Disease and Cognitive Impairment

The evidence for NADH in Alzheimer's disease (AD) is mixed and cannot be considered established. There is increasing evidence for diminished cerebral mitochondrial metabolism in Alzheimer patients. Considering the relatively small safety margin between energy supply and neuronal function and the known age-related changes in mitochondrial function, it has been thought that an exogenous supply of reducing equivalents for the energy metabolism could counteract age-related deficits in cognitive function.

One positive small trial was published: this study was designed to evaluate the effect of stabilized oral NADH on cognitive functioning in patients with Alzheimer's disease. NADH is a coenzyme that plays a key role in cellular energy production and stimulates dopamine production. In previous trials NADH has been shown to improve cognitive functioning in patients with Parkinson's disease, depression, and AD. The present trial was a randomized, placebo-controlled, matched-pairs, double-blind, 6-month clinical study. Patients with probable AD (n = 26) were randomized to receive either stabilized oral NADH (10 mg/day) or placebo. After 6 months of treatment, subjects treated with NADH showed no evidence of progressive cognitive deterioration and had significantly higher total scores on the Mattis Dementia Rating Scale compared with subjects treated with placebo. There were no differences between groups in measures of attention, memory, or in clinician ratings of dementia severity.

A contradicting open-label study found different results: reduced nicotinamide adenine dinucleotide (NADH) is advertised as an over-the-counter product or dietary supplement to treat Alzheimer's disease. A 3-month open-label study with oral 10 mg/day NADH was conducted in 25 patients with mild to moderate dementia of the Alzheimer, vascular, and fronto-temporal types in addition to their current cholinomimetic drug medication. In 19 patients who completed the study, no evidence was found for any cognitive effect as defined by established psychometric tests. The conclusion was that NADH is unlikely to achieve cognitive improvements in an extent reported earlier.

Given the contradictory results from small trials and at least one open-label study showing no benefit, NADH is considered ineffective for mild to moderate dementia from Alzheimer's disease by some clinical reviewers. The overall evidence does not support recommending NADH as a treatment for AD.

Parkinson's Disease

Early research on NADH in Parkinson's disease was conducted primarily through parenteral (intravenous and intramuscular) administration in European clinical settings. The Birkmayer group reported improvements in motor function and dopamine-related parameters in open-label studies. Clinical studies demonstrated positive effects of peripherally given NADH on serious disorders such as Parkinson's disease and chronic fatigue syndrome.

However, when more rigorous trial designs were applied to oral NADH: study results don't agree about the effectiveness of NADH in treating Parkinson's disease. Study results have been inconsistent regarding the effectiveness of NADH in treating Parkinson's disease. The proposed mechanism—stimulation of endogenous dopamine synthesis via tetrahydrobiopterin recycling—is biochemically plausible, but robust, large-scale randomized controlled trials examining oral NADH supplementation specifically in Parkinson's disease are lacking. Most positive evidence comes from small, open-label, or uncontrolled studies that are at high risk of bias.

Depression

NADH suggested uses include treating chronic fatigue syndrome, improving mental clarity, alertness, and concentration, depression, jet lag, high blood pressure, Parkinson's disease, and Alzheimer's disease. There is insufficient information on the effectiveness of NADH. Positive results are only from pilot studies or open-label studies. For depression specifically, no well-powered placebo-controlled trials of oral NADH have been published; the evidence is limited to early-phase pilot work.

Cardiovascular Health (Blood Pressure and Lipids)

There is some evidence that suggests NADH supplements might reduce blood pressure and lower cholesterol, but there isn't enough information to know for sure how or if these supplements work. A modest signal for blood-pressure reduction has appeared in some studies examining NADH in the context of ME/CFS research (particularly the finding of reduced maximum heart rate during exercise testing), but dedicated cardiovascular trials are absent from the literature.

Athletic Performance and Energy

Some small studies have examined NADH in the context of athletic performance. Studies performed by Dr. G.D. Birkmayer and team have shown some results with 20 milligrams of daily NADH supplementation in athletes. Participants found less lactic acid-related muscle fatigue after prolonged activity. This means that athletes could perform longer, and the recovery period between training sessions could be shorter. Users also found approximately 7% more energy, which is likely due to the fact that NADH triggers ATP production—the basic energy source of all cells. These findings, however, come from the Birkmayer research group and have not been independently replicated in peer-reviewed, large-scale trials.

Aging and Longevity

Some research has found that NADH may play an important role in cell aging, and that your body makes less NADH as you age. Your cells need NADH to make energy, and it may also play a role in aging, so there is interest in using NADH to slow aging, increase energy levels, and treat a wide variety of conditions. Total levels of NAD decline with age in a tissue-specific manner, thereby playing a significant role in the aging process. Supplementation with NAD precursors boosts total cellular NAD levels and provides some therapeutic benefits in human clinical trials. However, the majority of this work pertains to NAD precursors (particularly NMN and NR) rather than to NADH directly. The question of whether direct NADH supplementation meaningfully restores cellular NAD pools in aged human tissues has not been conclusively established.

There are many unknowns regarding pharmacokinetics and pharmacodynamics, particularly bioavailability, metabolism, and tissue specificity of NAD+ boosters. Given the lack of long-term safety studies, there is a need for more clinical trials to determine the proper dose of NAD+ boosters and treatment duration for aging prevention and as disease therapy.

5. Body Systems and Health Areas Associated with NADH

• Mitochondrial/Energy Metabolism: Central role as the primary electron donor to Complex I of the mitochondrial electron transport chain; directly linked to cellular ATP production in every cell type.
• Nervous System: NADH, a co-substrate for energy transfer in the mitochondrial respiratory chain, is speculated to induce positive effects in some degenerative disorders of the central nervous system. It also contributes to neurotransmitter synthesis.
• Cardiovascular System: Implicated in heart muscle energy metabolism; some evidence from ME/CFS studies suggests effects on exercise heart rate.
• Immune System: NADH is directly involved in the body's cellular immune defensive system. The 2024 systematic review also noted that NAD supplementation has been discussed as a therapeutic intervention for immunity decline and chronic inflammation.
• Musculoskeletal System: Relevant to muscle energy metabolism; animal studies and early human data have examined effects on muscle fatigue.
• Metabolic/Endocrine: Supplementation with NADH was associated with increased muscle insulin sensitivity and insulin signaling.
• Redox/Antioxidant Systems: The NAD+/NADH ratio is mainly involved in redox reactions since both molecules are responsible for carrying electrons to maintain redox homeostasis. NADH acts as a reducing agent, and one of the most known processes exploiting NADH function is energy metabolism.

6. Dosage Forms and Dosages Reported in Studies

NADH supplements are available in multiple forms, including enteric-coated tablets, sublingual lozenges, and oral capsules. Because NADH is unstable when exposed to heat, light, and moisture, enteric coating and specialized stabilization processes are used in commercially and clinically tested preparations.

The following dosages have been reported specifically in cited clinical research:

• Patients with probable Alzheimer's disease (n = 26) were randomized to receive either stabilized oral NADH 10 mg/day or placebo.
• A 3-month open-label study used oral 10 mg/day NADH in 25 patients with mild to moderate dementia.
• An 8-week, randomized, double-blind placebo-controlled trial evaluated oral CoQ10 (200 mg/day) plus NADH (20 mg/day) supplementation in 73 CFS patients.
• A 12-week prospective trial used CoQ10 (200 mg) and NADH (20 mg) once daily in 207 patients with ME/CFS.
• Researchers have used 10 mg per day, taken with water only, on an empty stomach.
• Typical supplemental dosages reported in the literature range from 5 to 50 mg daily, often administered sublingually.
• The available NAD supplementation found commercially can be found in various forms, such as NADH, NAD+, NAM, and NR, with dosages ranging from 4 mg/day to 1,000 mg/day administered orally.

The appropriate dose of NADH depends on several factors such as the user's age, health, and other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for NADH.

7. Safety Considerations and Interactions

General Tolerability

NADH supplementation is safe and has a low incidence of side effects. Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered. Based on studies, the supplementation with NADH and precursors was well tolerated and observed clinical results included a decrease in anxiety conditions and maximum heart rate after a stress test, and increased muscle insulin sensitivity. Quality of life, fatigue intensity, and sleep quality among others were evaluated on patients with CFS.

Adverse Effects Reported in Clinical Trials

All studies showed some side effects; the most common associated with NAD use are muscle pain, nervous disorders, fatigue, sleep disturbance, and headaches. All adverse events cataloged by the studies did not present a serious risk to the health of the participants. Gastrointestinal effects (notably nausea and upset stomach) have also been noted in some formulations.

Drug Interactions

NADH has no known severe interactions with other drugs. No well-documented, clinically significant pharmacokinetic or pharmacodynamic drug–drug interactions involving oral NADH have been established in the published literature to date.

Pregnancy and Breastfeeding

Due to a lack of safety data in humans, supplements of this product are not recommended during breastfeeding. Safety data in pregnancy is also insufficient to draw conclusions.

Regulatory Status and Product Quality

The FDA has not reviewed NADH for safety and effectiveness. The FDA has not tested NADH products to confirm that they contain the ingredients stated on their labels. Because commercial NADH is chemically labile, product quality, stability, and actual NADH content can vary substantially across preparations. Consumers are advised to look for products that have undergone third-party testing for identity, purity, and potency.

Confusion with Related Compounds

NADH should not be confused with ingredients that have similar names, such as nicotinamide (also known as niacinamide) and nicotinamide riboside. These are distinct molecules with different pharmacological profiles and evidence bases, and they should not be treated as interchangeable.

Long-Term Safety

Given the lack of long-term safety studies, there is a need for more clinical trials to determine the proper dose of NAD+ boosters and treatment duration for aging prevention and as disease therapy. Further research will also need to address the long-term consequences of increased NAD+ and the best approaches and combinations to increase NAD+ levels. The absence of long-term safety data is a meaningful limitation for all NAD-related supplementation.

References

• EBSCO Research Starters — Nicotinamide Adenine Dinucleotide as a Therapeutic Supplement
• Evaluation of Safety and Effectiveness of NAD in Different Clinical Conditions: A Systematic Review — PubMed (American Journal of Physiology, 2024)
• Effect of Dietary CoQ10 Plus NADH Supplementation on Fatigue Perception and HRQoL in ME/CFS: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial — PMC
• Effect of CoQ10 Plus NADH Supplementation on Maximum Heart Rate After Exercise Testing in Chronic Fatigue Syndrome — Clinical Nutrition Journal
• Does Oral CoQ10 Plus NADH Supplementation Improve Fatigue and Biochemical Parameters in Chronic Fatigue Syndrome? — PMC
• Treatment of Alzheimer's Disease with Stabilized Oral Nicotinamide Adenine Dinucleotide: A Randomized, Double-Blind Study — PubMed
• No Evidence for Cognitive Improvement from Oral NADH in Dementia — PubMed
• Stabilized NADH as a Countermeasure for Jet Lag — NASA Technical Reports Server
• Treatment with Reduced Nicotinamide Adenine Dinucleotide (NADH) Improves Water Maze Performance in Old Wistar Rats — ScienceDirect (Behavioural Brain Research, 2004)
• NADH Stimulates Endogenous Dopamine Biosynthesis by Enhancing the Recycling of Tetrahydrobiopterin in Rat Phaeochromocytoma Cells — ScienceDirect (BBA, 1997)
• NAD(H) in Mitochondrial Energy Transduction: Implications for Health and Disease — PMC
• NAD+ Metabolism and Its Roles in Cellular Processes During Ageing — PMC
• Current Uncertainties and Future Challenges Regarding NAD+ Boosting Strategies — PMC
• The Plasma NAD+ Metabolome Is Dysregulated in "Normal" Aging — PMC
• Age-Related Changes in NAD+ Metabolism, Oxidative Stress and Sirt1 Activity in Wistar Rats — PMC
• Nicotinamide Adenine Dinucleotide: The Redox Sensor in Aging-Related Disorders — PubMed (Antioxidants & Redox Signaling, 2024)
• Emerging Therapeutic Roles for NAD+ Metabolism in Mitochondrial and Age-Related Disorders — PMC
• Physiology, Adenosine Triphosphate — StatPearls, NCBI Bookshelf
• NADH — Health Information Library, PeaceHealth
• NADH: Health Benefits, Side Effects, Uses, Dose & Precautions — RxList
• NADH: Overview, Uses, Side Effects, Precautions, Interactions, Dosing — WebMD
• Coenzyme Q10 Plus NADH Supplementation in CFS/Myalgic Encephalomyelitis — ClinicalTrials.gov NCT03186027
• Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions — PMC